3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Cisplatin
13
Magnetic Resonance Spectroscopy
9
Specimen Handling
8
Radiotherapy
7
Platinum
7
1,2-diaminocyclohexaneplatinum II citrate
7
Radiotherapy, Intensity-Modulated
4
Radiation
4
Biopsy
4
Surveys and Questionnaires
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
durvalumab
2
Observation
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
Docetaxel
2
Disulfides
2
Chemoradiotherapy
2
Cetuximab
2
(225)Ac-DOTA-c(RGDyK)
2
niraparib
1
merphos
1
ipatasertib
1
dostarlimab
1
cemiplimab
1
cabozantinib
1
balstilimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Oropharyngeal Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.